Scientists use multi-day live cell assays to monitor cell growth, viability, and cytotoxicity when evaluating the effects of drug treatment. However, maintaining consistent cell health over time ...

This article is based on a poster originally authored by Yongyang Huang, Ning Guo, Mackenzie Pierce, Leo Chan, Bo Lin and Yi Yang, which was presented at ELRIG Drug Discovery 2024 in affiliation with ...

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...